author

 
 

Meta

John Lauerman
For John Lauerman's latest contributions to The Japan Times, see below:
Japan Times
BUSINESS / Companies
Dec 14, 2022
Takeda to pay up to $6 billion for Nimbus immune-therapy drug
After an initial $4 billion payment upfront, U.S.-based Nimbus is eligible for two additional $1 billion payments based on sales.
Japan Times
WORLD
Mar 12, 2022
WHO exploring when and how to declare end of COVID emergency
Such a declaration would be not just a meaningful symbolic step, and would add momentum to the rollback of many pandemic-era public health policies.
Japan Times
WORLD
May 6, 2021
Vaccines work on this India variant. Experts fret about the next.
As infections surge by more than 300,000 cases for 14 straight days, India's limited ability to track new mutations emerging from its outbreak is a growing concern for scientists.
Japan Times
WORLD / Science & Health
Apr 14, 2021
Vaccine blood-clot side effect puts focus on immune reaction
Health officials are exploring whether and how an immune reaction may occur in people who have received vaccines made by AstraZeneca and Johnson & Johnson.
Japan Times
WORLD / Science & Health
Dec 21, 2020
Vaccines don’t mean we’ll see the last of COVID-19, experts warn
Even with the latest technologies, money and might behind the unprecedented global drive to knock out COVID-19, the disease is unlikely to be eliminated any time soon.
Japan Times
ASIA PACIFIC / FOCUS
Feb 24, 2020
As pandemic looms, world's top disease fighter engages Xi in delicate quest for cooperation
Tedros Adhanom Ghebreyesus has perhaps the most thankless job in global public health. As director-general of the World Health Organization, the former Ethiopian health minister is racing against time to prevent a dangerous new coronavirus in China from precipitating a worldwide pandemic.
Japan Times
BUSINESS
Oct 27, 2018
Trump springs globalist surprise with medicare drug-pricing plan
A drug-pricing plan unveiled by the Trump administration has put the U.S. on a path toward policies like those in Europe, where governments use tight cost controls.
Japan Times
BUSINESS / Companies
Mar 29, 2018
Takeda shares slide amid $50 billion takeover bid for Shire
Shares of Takeda Pharmaceutical Co. fell the most in nine years after the firm disclosed it is considering a bid for Shire PLC that could approach $50 billion (about ¥5.3 trillion), which would be the Japanese company’s biggest takeover ever.

Longform

High-end tourism is becoming more about the kinds of experiences that Japan's lesser-known places can provide.
Can Japan lure the jet-set class off the beaten path?